Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial
- Author(s)
- Mateo, J; de Bono, JS; Fizazi, K; Saad, F; Shore, N; Sandhu, S; Chi, KN; Agarwal, N; Olmos, D; Thiery-Vuillemin, A; Özgüroğlu, M; Mehra, N; Matsubara, N; Young Joung, J; Padua, C; Korbenfeld, E; Kang, J; Marshall, H; Lai, Z; Barnicle, A; Poehlein, C; Lukashchuk, N; Hussain, M;
- Details
- Publication Year 2024-02-10,Volume 42,Issue #5,Page 571-583
- Journal Title
- Journal of Clinical Oncology
- Publication Type
- Research article
- Abstract
- Olaparib improved PFS and OS across subgroups of BRCA1/2mut #prostatecancer patients in the PROFOUND phase III trial.
- Publisher
- American Society of Clinical Oncology
- Keywords
- Humans; Male; BRCA1 Protein/genetics; BRCA2 Protein/genetics; Kaplan-Meier Estimate; Phthalazines/therapeutic use; Piperazines/therapeutic use; *Prostatic Neoplasms, Castration-Resistant/drug therapy/genetics
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1200/jco.23.00339
- Open Access at Publisher's Site
https://doi.org/10.1200/jco.23.00339- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2024-03-13 05:27:09
Last Modified: 2024-03-13 05:27:28